Vaclav Volrab / Shutterstock.com
Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain.
Whether it is to replenish innovator pharmaceutical companies’ diminishing new product pipelines or because of the allure of new platform technologies, the life sciences industry has been an active sector for transactions of various kinds.
These transactions have come in the form of partnerships, joint ventures, licences, and mergers and acquisitions. Life sciences companies typically rely on patent and regulatory exclusivity to recover the enormous costs associated with developing and bringing a product to market before generic or biosimilar competition drives profits down.
This means that intellectual property (in particular, patents) is often one of the most valuable assets of a life sciences company, particularly an early stage company, which does not have a revenue stream. Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Karen Mangasarian, Ryan Murphey, Ropes & Gray, freedom to operate, patent, trademark, copyright, FTO, USPTO, PTE, FDA,